PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Galanthamine, an alkaloid extracted from Galanthus, is used and marketed as a symptomatic treatment for Alzheimer's disease due to its acetylcholinesterase inhibitory activity [PMID:37397105, PMID:11060814].
Evidence summary
PubMed sources
- 1.PMID: 33679383 (2020) — Biological Activities of Snowdrop (Galanthus spp., Family Amaryllidaceae). · Frontiers in pharmacology
- 2.PMID: 37397105 (2023) — Therapeutic and medicinal effects of snowdrop (Galanthus spp.) in Alzheimer's disease: A review. · Journal of education and health promotion
- 3.PMID: 21259423 (2011) — Alkaloid diversity in Galanthus elwesii and Galanthus nivalis. · Chemistry & biodiversity
- 4.PMID: 17475295 (2007) — Alkaloids from Galanthus nivalis. · Phytochemistry
- 5.PMID: 11060814 (2000) — Review of the acetylcholinesterase inhibitor galanthamine. · Expert opinion on investigational drugs